Bevacizumab toxicities and their management in ovarian cancer

Gynecologic Oncology

Volumn 117, Issue 3, 2010, Pages 497-504

  Randall, Leslie M ^a   Monk, Bradley J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bevacizumab; Ovarian cancer; Toxicity

Indexed keywords

ALPHA INTERFERON; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PLACEBO; TOPOTECAN; VASCULOTROPIN;

ARTERY THROMBOSIS; BRAIN INFARCTION; CANCER REGISTRY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIASTOLIC BLOOD PRESSURE; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DRY SKIN; EPISTAXIS; EXFOLIATIVE DERMATITIS; FISTULA; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; INCIDENCE; INTESTINE PERFORATION; LACRIMATION DISORDER; LUNG EMBOLISM; MORBIDITY; MORTALITY; NEPHROTIC SYNDROME; OVARY CANCER; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROTEINURIA; RECTUM HEMORRHAGE; REVIEW; RHINITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TASTE DISORDER; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; HYPERTENSION; INTESTINAL PERFORATION; OVARIAN NEOPLASMS;

EID: 77951937790     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.02.021     Document Type: Review

References (48)

1. Burger R.A. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 25 20 (Jul 10 2007) 2902-2908
2. Kerbel R.S. Tumor angiogenesis. N Engl J Med 358 19 (May 8 2008) 2039-2049
3. Fukumura D., and Jain R.K. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 74 2-3 (Sep-Nov 2007) 72-84
4. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 5 (May 2004) 391-400
5. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (Jun 3 2004) 2335-2342
6. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 24 (Dec 14 2006) 2542-2550
7. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 26 (Dec 27 2007) 2666-2676
8. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 9605 (Dec 22 2007) 2103-2111
9. Kreisl T.N., Kim L., Moore K., Duic P., Royce C., Stroud I., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27 5 (Feb 10 2009) 740-745
10. Friedman H.S., Prados M.D., Wen P.Y., Mikkelsen T., Schiff D., Abrey L.E., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Internet 27 (2009) 4733-4740 [published online 2009 Aug 31; cited 2009 Aug 11]
11. Burger R.A., Sill M.W., Monk B.J., Greer B.E., and Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 25 33 (Nov 20 2007) 5165-5171
12. Cannistra S.A., Matulonis U.A., Penson R.T., Hambleton J., Dupont J., Mackey H., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25 33 (Nov 20 2007) 5180-5186
13. McGonigle K.F., Muntz H.G., Vuky J.L., Paley P.J., Veljovich D.S., Gray H.J., et al. Phase II prospective study of weekly topotecan and bevacizumab in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol [abstract 286] 112 2 suppl 1 (Feb 2009) S145
14. Garcia A.A., Hirte H., Fleming G., Yang D., Tsao-Wei D.D., Roman L.L., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26 1 (Jan 1 2008) 76-82
15. Nimeiri H.S., Oza A.M., Morgan R.J., Friberg G., Kasza K., Faoro L., et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 110 1 (Jul 2008) 49-55
16. ClinicalTrials.gov. A phase III trial of carboplatin and paclitaxel plus placebo versus carboplatin and paclitaxel plus concurrent bevacizumab (NSC # 704865, IND #7921) followed by placebo, versus carboplatin and paclitaxel plus concurrent and extended bevacizumab, in women with newly diagnosed, previously untreated, suboptimal advanced stage epithelial ovarian, primary peritoneal, or fallopian tube cancer [Internet]. U S National Institutes of Health; 2005 Dec [updated 2009 Jul; cited 2009 Aug 11]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00262847.
17. ClinicalTrials.gov. ICON7-a randomised, two-arm, multi-centre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer [Internet]. U S National Institutes of Health; 2007 Jun [updated 2007 Sept; cited 2009 Aug 11]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00483782.
18. ClinicalTrials.gov. A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab (NSC #704865, IND #7921) followed by bevacizumab and secondary cytoreduction surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer [Internet]. U S National Institutes of Health; 2007 Nov [updated 2009 Aug; cited 2009 Aug 11]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00565851.
19. ClinicalTrials.gov. A Study of carboplatin and gemcitabine plus bevacizumab in patients with ovary, peritoneal, or fallopian tube carcinoma (OCEANS) [Internet]. U S National Institutes of Health; 2007 Feb [updated 2009 April; cited 2009 Aug 11]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00434642.
20. Allegra C.J., Yothers G., O'Connell M.J., Sharif S., Colangelo L.H., Lopa S.H., et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 27 20 (Jul 10 2009) 3385-3390
21. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27 8 (Mar 10 2009) 1227-1234
22. Saltz L.B., Clarke S., Díaz-Rubio E., Scheithauer W., Figer A., Wong R., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26 12 (Apr 20 2008) 2013-2019
23. Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 25 12 (Apr 20 2007) 1539-1544
24. Miller K.D., Chap L.I., Holmes F.A., Cobleigh M.A., Marcom P.K., Fehrenbacher L., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 4 (Feb 1 2005) 792-799
25. Avastin [package insert] (2009), Genentech Inc, South San Francisco (CA)
26. Hedrick E., Kozloff M., Hainsworth J., et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BriTE). J Clin Oncol 24 18S (2006) 3536 [abstract 3536]
27. Van Cutsem E., Rivera F., Berry S., Kretzschmar A., Michael M., Dibartolomeo M., et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol [Internet] 20 (2009) 1842-1847 [published online 2009 Apr 30; cited 2009 Aug 11]
28. Herzog T.J., Rose P.G., Braly P.S., Hines J.F., Bell M.C., Wenham R.M., et al. Preliminary safety results of TEACO, a phase 2 trial of oxaliplatin, docetaxel and bevacizumab as first-line therapy for advanced cancer of the ovary, peritoneum and fallopian tube. Gynecol Oncol 112 2 suppl 1 (2009) S27 [abstract 48]
29. Cancer Therapy Evaluation Program. Common toxicity criteria for adverse events, version 3.0 (CTCAE) [Internet]. National Cancer Institute; 2006 Aug [cited 2009 Aug 11]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
30. Zhu X., Wu S., Dahut W.L., and Parikh C.R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2 (Feb 2007) 186-193
31. Azad N.S., Posadas E.M., Kwitkowski V.E., Steinberg S.M., Jain L., Annunziata C.M., et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26 22 (Aug 1 2008) 3709-3714
32. Kamba T., and McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96 12 (Jun 18 2007) 1788-1795
33. Steeghs N, Rabelink TJ, op 't Roodt J, de Koning E, Gelderblom H. Bevacizumab-related hypertension: search for underlying mechanisms. J Clin Oncol [abstract e14520 on Internet]. 2009 [cited 2009 Aug 11];27(15S). Available from: http://meeting.ascopubs.org/cgi/content/abstract/27/15S/e14520?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=e14520+&searchid=1&FIRSTINDEX=0&volume=27&issue=15S&resourcetype=HWCIT.
34. Gurevich F., and Perazella M.A. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 122 4 (Apr 2009) 322-328
35. Sugimoto H., Hamano Y., Charytan D., Cosgrove D., Kieran M., Sudhakar A., et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278 15 (2003) 12605-12608
36. Eremina V., Jefferson A., Kowalewska J., Hochster H., Haas M., Weisstuch J., et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358 (2008) 1129-1136
37. Torng S., Rigatto C., Rush D.N., Nickerson P., and Jeffery J.R. The urine protein tocreatinine ratio (P/C) as a predictor of 24-hour urine protein excretion in renal transplant patients. Transplantation 72 8 (Oct 27 2001) 1453-1456
38. Avastin [package insert] (2004), Genentech Inc, South San Francisco (CA)
39. Hapani S., Chu D., and Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10 6 (Jun 2009) 559-568
40. Han E.S., and Monk B.J. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?. Gynecol Oncol 105 1 (Apr 2007) 3-6
41. Diaz J.P., Zivanovic O., Tew W.P., Konner J., Sabbatini P.J., Abu-Rustum N.R., et al. Incidence and management of bevacizumab-associated gastrointestinal perforation in patients with recurrent ovarian carcinoma. Gynecol Oncol [abstract 269] 112 2 suppl 1 (2009) S137
42. Richardson D.L., Backes F.J., Hurt J.D., Seamon L.G., Copeland L.J., Fowler J.M., et al. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer treated with bevacizumab?. Gynecol Oncol [abstract 41] 112 2 suppl 1 (2009) S23
43. Sugrue M., Kozloff M., Hainsworth J., Badarinath S., Cohn A., Flynn P., et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol [abstract 3535] 24 18 S (Jun 20 2006) 154s
44. Verheul H.M.W., and Pinedo H.M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7 6 (Jun 2007) 475-485
45. Scappaticci F.A., Skillings J.R., Holden S.N., Gerber H.P., Miller K., Kabbinavar F., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 99 16 (Aug 15 2007) 1232-1239
46. Nalluri S.R., Chu D., Keresztes R., Zhu X., and Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients. JAMA. 300 19 (Nov 19 2008) 2277-2285
47. Scappaticci F.A., Fehrenbacher L., Cartwright T., Hainsworth J.D., Heim W., Berlin J., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91 3 (Sep 1 2005) 173-180
48. Sugrue M.M., Purdie D.M., Feng S., Flynn P.J., Grothey A., Sargent D.J., et al. Serious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): results from the BRiTE observational cohort study (OCS). J Clin Oncol [abstract 4105] 26 15S (May 20 2008) 204s